Evidence-Based Summary
Semax and Selank are both synthetic heptapeptides developed by the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s and 1990s, sharing an identical C-terminal tripeptide stabilization sequence (Pro-Gly-Pro) that protects them from rapid enzymatic degradation in human nasal mucosa and serum. However, their biological lineages and primary psychological indications are completely distinct. Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10). It is devoid of hormonal corticosteroid activity; instead, it acts as a central neurotrophic stimulant, potently upregulating brain-derived neurotrophic factor (BDNF) and its TrkB receptor, stimulating dopaminergic and serotonergic turnover, and improving attention and memory. In Russia, Semax is approved for ischemic stroke rehabilitation, optic nerve disease, and transient cognitive fatigue. In contrast, Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is derived from the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg). Selank functions primarily as an anxiolytic: it allosterically modulates GABA-A receptors, stabilizes endogenous enkephalins by inhibiting peptidases, and reduces anxiety and emotional tension without causing sedation, muscle relaxation, or addiction common to benzodiazepines. Neither peptide is approved by the U.S. FDA or European EMA, and both remain unregulated investigational compounds in Western jurisdictions.
Quick Comparison: Semax vs Selank
A high-level comparison of molecule class, molecular receptor targets, FDA regulatory approvals, and verified clinical programs.
| Feature | Semax | Selank |
|---|---|---|
| Biological lineage | Derived from adrenocorticotropic hormone: ACTH(4-10) | Derived from endogenous immune tetrapeptide: Tuftsin |
| Amino acid sequence | Met-Glu-His-Phe-Pro-Gly-Pro (813.9 g/mol) | Thr-Lys-Pro-Arg-Pro-Gly-Pro (751.9 g/mol) |
| Stabilizing motif | C-terminal Pro-Gly-Pro (PGP) tripeptide cap | C-terminal Pro-Gly-Pro (PGP) tripeptide cap |
| Primary neurochemical target | BDNF / TrkB upregulation, dopamine & serotonin turnover | GABA-A allosteric modulation, enkephalin stabilization |
| Primary cognitive/emotional effect | Cognitive enhancement, attention, alertness, neuroprotection | Anxiolysis, stress mitigation, emotional stabilization |
| Sedative / Addiction risk | Non-sedating; no dependence observed | Non-sedating; does not cause benzodiazepine-like withdrawal |
| Approved indications (Russia/CIS) | Ischemic stroke, optic nerve atrophy, intellectual fatigue | Generalized anxiety disorder, neurasthenia, adjustment disorders |
| FDA / EMA regulatory status | Unapproved investigational compound | Unapproved investigational compound |
BDNF Neurotrophin Activation vs GABAergic Anxiolysis
The contrasting neurochemical mechanisms underlying stimulation versus emotional calming.
Semax: BDNF-TrkB Upregulation & Neuroprotection
Primary Target: Neurotrophin pathway, melanocortin receptor cross-talk
Affinity Profile: High central bioactivity following intranasal delivery
Semax rapidly crosses the cribriform plate into the central nervous system. In the hippocampus and frontal cortex, it triggers a rapid 2- to 3-fold increase in mRNA and protein expression of brain-derived neurotrophic factor (BDNF) and its receptor TrkB. This promotes dendritic spine remodeling, enhances long-term potentiation (LTP), protects neurons against glutamate excitotoxicity during ischemia, and accelerates dopaminergic synthesis.
Selank: GABA-A Modulation & Enkephalin Protection
Primary Targets: GABA-A receptor allosteric site; enkephalinase inhibition
Affinity Profile: Nanomolar neuromodulatory potency
Selank binds allosterically to GABA-A receptors, enhancing inhibitory GABAergic transmission in the amygdala and limbic circuits, which reduces acute stress reactivity and anxiety. Concurrently, Selank inhibits carboxypeptidase and enkephalinase enzymes in human plasma, preventing the breakdown of endogenous enkephalins and supporting sustained emotional equilibrium and immune resilience.
Russian State Register of Medicines vs Western Unapproved Status
Semax and Selank possess official drug registration in the Russian Federation but remain unapproved in the US and Europe.
Semax Status & Formulations
Not approved by the FDA or EMA for human clinical use.
Selank Status & Formulations
Not approved by the FDA or EMA for human clinical use.
Critical Regulatory Distinction
Semax (0.1% and 1.0% nasal drops) and Selank (0.15% nasal drops) are listed on the Russian State Register of Medicines. However, neither peptide has been submitted for FDA NDA or EMA marketing approval.
Russian Clinical Trials & Mechanistic Studies
Evaluating the published peer-reviewed evidence for both neuropeptides.
Semax: Semax Clinical Literature
In Russian multicenter clinical trials in patients with acute ischemic stroke (Gusev et al., Zh Nevrol Psikhiatr 2018), Semax 1.0% administered within the first hours of stroke onset significantly improved functional neurological recovery scores and reduced 30-day disability compared to standard supportive care.
Selank: Selank Clinical Literature
Clinical trials in patients with generalized anxiety disorder and neurasthenia (Kost et al., Medline/Scopus 2008) demonstrated that Selank 0.15% produced anxiolytic effects comparable to low-dose medazepam, but without daytime drowsiness, muscle weakness, memory impairment, or withdrawal symptoms.
Adverse Reactions & Tolerability
Both peptides exhibit low toxicity profiles in nasal drop formulations.
| Safety Consideration | Semax | Selank |
|---|---|---|
| Sedation / Motor impairment | None (Mildly stimulating) | None (Non-sedating anxiolytic) |
| Nasal mucosa irritation | Mild transient burning with 1% formulation | Rare mild local irritation |
| Tolerance and dependence | No dependence or withdrawal reported | No withdrawal syndrome; does not bind benzodiazepine site directly |
What Semax and Selank Have in Common
Where the two compounds overlap in biology, evidence or regulatory context.
Russian Academy of Sciences Origin
Both peptides were developed by the same research group using an identical Pro-Gly-Pro enzymatic stabilization cap.
Intranasal Administration
Both are formulated as aqueous intranasal drops designed to bypass the blood-brain barrier via olfactory pathways.
Key Scientific & Clinical Differences
Meaningful distinctions in mechanism, strength of evidence, safety and regulatory status.
Primary Indication
Semax is an activating nootropic and neuroprotective agent; Selank is a calming anxiolytic and emotional stabilizer.
Parent Molecule
Semax derives from ACTH(4-10); Selank derives from the immune tetrapeptide tuftsin.
Neurochemical Target
Semax targets BDNF, TrkB, and dopamine; Selank targets GABA-A and enkephalin preservation.
Scientific Comparison vs Clinical Recommendations
Inside Peptides compares scientific evidence, receptor pharmacology, and official regulatory documents to advance public and professional understanding. We do not determine which compound is appropriate for an individual patient, rank medications with arbitrary scores, or recommend initiating or switching treatments.
Decisions about any medicine require a licensed healthcare professional who can weigh personal medical history, contraindications, interactions and monitoring needs. Unapproved peptides have no established safe use, and products sold as “research chemicals” are not the preparations studied in clinical research.
Approved Uses vs Online Claims
A critical scientific distinction between verified, FDA-approved clinical uses and unverified claims circulating on social media and vendor platforms.
Semax and Selank are identical limitless pills that cure ADHD and anxiety
insufficientUnapproved neuropeptides with no FDA clearance for ADHD, depression, or anxiety.
While each neuropeptide has distinct, well-documented actions in Russian medical literature, Western online vendors sell uncertified research solutions that lack pharmaceutical sterility, proper dosage controls, and FDA validation.
Evidence Strength Across Clinical Domains
Inside Peptides evaluates scientific certainty at the claim level. Because clinical evidence varies significantly depending on the therapeutic endpoint evaluated, each domain is assessed independently.
Acute Stroke & Cognitive Fatigue
Semax demonstrated in Russian clinical trials; Western independent replication lacking.
Generalized Anxiety & Stress Mitigation
Selank validated in Russian psychiatric trials; Western independent replication lacking.
What Research Still Doesn’t Tell Us
Identifying open scientific questions, pending active-comparator trials, and areas where long-term clinical data remain incomplete.
Western Multicenter Replicative Trials
Conducting double-blind, randomized, placebo-controlled trials under ICH-GCP guidelines in North American and European academic centers.
Related Compound Profiles
Individual profiles provide full molecular datasheets, CAS numbers, preclinical histories, and compound monographs.
Related Educational Resources
Scientific & Regulatory References
Every pharmacological mechanism, clinical trial result, and regulatory approval cited on this page is traceable to official FDA prescribing documentation, ClinicalTrials.gov registries, or peer-reviewed medical publications.
-
Preclinical Study
Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action
-
In Vitro Study
GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells